WHO ICTRP trial
Additief antiproteinurisch effect van de vitamine D analoog paricalcitol.
NL-OMON22539 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON22539 |
|---|---|
| Public title | Additief antiproteinurisch effect van de vitamine D analoog paricalcitol. |
| Scientific title | Vitamin D in addition to RAAS blockade and dietary sodium for the Treatment of Urinary Excretion of albumin. |
| Primary sponsor | University Medical Center Groningen |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Conditions | proteinuria proteinurie albuminuria albuminurie chronic kidney disease chronisch nierfalen non-diabetic renal disease niet-diabetische nierziekte paricalcitol zemplar vitamin D receptor activator vitamine D receptor activator vitamin D… |
| Interventions | The study question will be addressed in a prospective, multiple-center, double-blind, crossover, randomized placebo-controlled clinical trial. Patients are consecutively treated during eight weeks with placebo or vitamin D analogue… |
| Registration date | May 11, 2011 |
| Target size | 50 |
| Secondary IDs | NL2759;NTR2898;METC UMCG / CCMO : 2009.272 / NL29900.042.09;;ISRCTN wordt niet meer aangevraagd. |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: